Literature DB >> 1648582

Effects of the antidepressant phenelzine on brain levels of gamma-aminobutyric acid (GABA).

G B Baker1, J T Wong, J M Yeung, R T Coutts.   

Abstract

Time- and dose-response studies were carried out on the effects of the monoamine oxidase-inhibiting antidepressant and antipanic drug phenelzine on GABA levels in rat whole brain. At a dose of 15 mg/kg i.p., phenelzine significantly elevated GABA levels at all time intervals studied (1, 2, 4, 8, 16, and 24 h). A further investigation indicated that this was a dose-dependent effect. The possible importance of GABA in the etiology and pharmacotherapy of depression and panic disorder is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1648582     DOI: 10.1016/0165-0327(91)90041-p

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  18 in total

Review 1.  Neurochemical and metabolic aspects of antidepressants: an overview.

Authors:  G B Baker; R T Coutts; A J Greenshaw
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

Review 2.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

Review 3.  Protective effects of phenelzine administration on synaptic and non-synaptic cortical mitochondrial function and lipid peroxidation-mediated oxidative damage following TBI in young adult male rats.

Authors:  Rachel L Hill; Indrapal N Singh; Juan A Wang; Jacqueline R Kulbe; Edward D Hall
Journal:  Exp Neurol       Date:  2020-04-20       Impact factor: 5.330

Review 4.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

5.  Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders?

Authors:  Glen B Baker; Bernard Sowa; Kathryn G Todd
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

Review 6.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

7.  The antidepressant drug phenelzine produces antianxiety effects in the plus-maze and increases in rat brain GABA.

Authors:  T Paslawski; D Treit; G B Baker; M George; R T Coutts
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

8.  Phenelzine causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition.

Authors:  Erin M MacKenzie; Suzanne L Grant; Glen B Baker; Paul L Wood
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  Effects of Phenelzine Administration on Mitochondrial Function, Calcium Handling, and Cytoskeletal Degradation after Experimental Traumatic Brain Injury.

Authors:  Rachel L Hill; Indrapal N Singh; Juan A Wang; Edward D Hall
Journal:  J Neurotrauma       Date:  2018-12-12       Impact factor: 5.269

10.  N2-acetylphenelzine: effects on rat brain GABA, alanine and biogenic amines.

Authors:  K F McKenna; G B Baker; R T Coutts
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.